Department of Radiation Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.
Laryngoscope. 2012 Aug;122(8):1789-95. doi: 10.1002/lary.23387.
OBJECTIVES/HYPOTHESIS: The main goal of the current study was to comprehensively address the impact of chemoradiation and radiation techniques on toxicity, quality of life (QoL), and functional outcome.
Retrospective analysis of toxicity and functional outcome and prospective QoL assessment.
From 1996 to 2010, 176 consecutive patients with hypopharyngeal cancer (HPC) were treated with (chemo)radiotherapy. End points were acute and late toxicity, QoL assessment, and functional outcome using laryngoesophageal dysfunction-free survival (LED-FS) defined by the Laryngeal Preservation Consensus Panel.
Chemoradiation significantly increased grade 3 acute toxicity compared to radiotherapy alone (71% vs. 55%, P = .02). The 3-year grade ≥2 late toxicity was 32%. Intensity-modulated radiotherapy (IMRT) significantly reduced late toxicity compared to three-dimensional conformal radiotherapy (3DCRT) (24% vs. 44%, P = .007). Slight deterioration in QoL scores was observed on almost all scales, and was more pronounced in patients treated with chemoradiation, albeit not statistically significant except for xerostomia. Chemoradiation, compared to radiotherapy alone, improved LED-FS at 3 years (51% vs. 24% for the entire group and 83% vs. 63% for the 78 living patients at last follow-up, respectively [P = .05]).
Compared to radiotherapy alone, chemoradiation significantly improved functional outcome, increased acute toxicity, but without significant increase in late radiation-induced side effects. Statistically significant deterioration in QoL scores was reported only for xerostomia. IMRT, compared to 3DCRT, reduced the incidence and severity of acute and late toxicity, thereby broadening the therapeutic window, and may allow dose escalation for further improvement of outcomes of laryngeal preservation protocols.
目的/假设:本研究的主要目标是全面评估放化疗和放疗技术对毒性、生活质量(QoL)和功能结果的影响。
毒性和功能结果的回顾性分析以及前瞻性 QoL 评估。
1996 年至 2010 年,176 例下咽癌(HPC)患者接受(放化疗)放疗。终点为急性和迟发性毒性、QoL 评估以及喉保留共识小组定义的喉保留功能无失败生存(LED-FS)的功能结果。
与单纯放疗相比,放化疗显著增加了 3 级急性毒性(71%比 55%,P=.02)。3 年时≥2 级迟发性毒性为 32%。与三维适形放疗(3DCRT)相比,调强放疗(IMRT)显著降低了迟发性毒性(24%比 44%,P=.007)。几乎所有量表的 QoL 评分都有轻微恶化,放化疗组更为明显,但除口干外,无统计学意义。与单纯放疗相比,放化疗在 3 年内改善了 LED-FS(整个组为 51%比 24%,78 例生存患者的最后随访分别为 83%比 63%[P=.05])。
与单纯放疗相比,放化疗显著改善了功能结果,增加了急性毒性,但未显著增加晚期放射性副作用。仅报告口干的 QoL 评分有统计学显著恶化。与 3DCRT 相比,IMRT 降低了急性和迟发性毒性的发生率和严重程度,从而扩大了治疗窗口,并可能允许提高剂量以进一步改善喉保留方案的结果。